Continuation Pharmacotherapy in the Prevention of Relapse Following Electroconvulsive Therapy - References - Continuation Pharmacotherapy in the Prevention of Relapse Following Electroconvulsive Therapy

Written by JAMA

REFERENCES

1-15 ~ 16-30 ~ 31-45 ~ 46-60 ~ 61-75

1.
American Psychiatric Association Committee on Electroconvulsive Therapy.
The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging.
2nd ed. Washington, DC: American Psychiatric Association; 2001.

2.
Thompson JW, Weiner RD, Myers CP.
Use of ECT in the United States in 1975, 1980, and 1986.
Am J Psychiatry.
1994;151:1657-1661.
MEDLINE

3.
Sackeim HA, Devanand DP, Nobler MS.
Electroconvulsive therapy.
In: Bloom F, Kupfer D, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven; 1995:1123-1142.

4.
Sackeim HA.
Continuation therapy following ECT: directions for future research.
Psychopharmacol Bull.
1994;30:501-521.
MEDLINE

5.
Karlinsky H, Shulman KI.
The clinical use of electroconvulsive therapy in old age.
J Am Geriatr Soc.
1984;32:183-186.

6.
Spiker DG, Stein J, Rich CL.
Delusional depression and electroconvulsive therapy: one year later.
Convulsive Ther.
1985;1:167-172.

7.
Aronson TA, Shukla S, Hoff A.
Continuation therapy after ECT for delusional depression: a naturalistic study of prophylactic treatments and relapse.
Convulsive Ther.
1987;3:251-259.

8.
Sackeim HA, Prudic J, Devanand DP, et al.
The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression.
J Clin Psychopharmacol.
1990;10:96-104.

9.
Malcolm K, Dean J, Rowlands P, Peet M.
Antidepressant drug treatment in relation to the use of ECT.
J Psychopharmacol.
1991;5:255-258.

10.
Sackeim HA, Prudic J, Devanand DP, et al.
Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy.
N Engl J Med.
1993;328:839-846.

11.
Grunhaus L, Shipley JE, Eiser A, et al.
Shortened REM latency post-ECT is associated with rapid recurrence of depressive symptomatology.
Biol Psychiatry.
1994;36:214-222.

12.
Lemstra A, Leentjens AF, van den Broek WW.
Temporary results only in electroconvulsive therapy in therapy-resistant depression: retrospective study.
Ned Tijdschr Geneeskd.
1996;140:260-264.

13.
O'Leary DA, Lee AS.
Seven-year prognosis in depression: mortality and readmission risk in the Nottingham ECT cohort.
Br J Psychiatry.
1996;169:423-429.

14.
Flint AJ, Rifat SL.
Two-year outcome of psychotic depression in late life.
Am J Psychiatry.
1998;155:178-183.

15.
Sackeim HA, Prudic J, Devanand DP, et al.
A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities.
Arch Gen Psychiatry.
2000;57:425-434.

16.
Seager CP, Bird RL.
Imipramine with electrical treatment in depression: a controlled trial.
J Ment Sci.
1962;108:704-707.

17.
Imlah NW, Ryan E, Harrington JA.
The influence of antidepressant drugs on the response to electroconvulsive therapy and on subsequent relapse rates.
Neuropsychopharmacology.
1965;4:438-442.

18.
Kay DW, Fahy T, Garside RF.
A seven-month double-blind trial of amitriptyline and diazepam in ECT-treated depressed patients.
Br J Psychiatry.
1970;117:667-671.

19.
Lauritzen L, Odgaard K, Clemmesen L, et al.
Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy.
Acta Psychiatr Scand.
1996;94:241-251.

20.
Abou-Saleh MT, Coppen AJ.
Continuation therapy with antidepressants after electroconvulsive therapy.
Convulsive Ther.
1988;4:263-268.

21.
American Psychiatric Association Committee on Electroconvulsive Therapy.
The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging.
Washington, DC: American Psychiatric Association; 1990.

22.
Royal College of Psychiatrists.
The ECT Handbook: The Second Report of the Royal College of Psychiatrists' Special Committee on ECT.
London, England: Royal College of Psychiatrists; 1995.

23.
Abrams R.
Electroconvulsive Therapy.
3rd ed. New York, NY: Oxford University Press; 1997.

24.
Sackeim HA, Prudic J, Devanand DP.
Treatment of medication-resistant depression with electroconvulsive therapy.
In: Tasman A, Goldfinger SM, Kaufmann CA, eds. Annual Review of Psychiatry. Vol 9. Washington, DC: American Psychiatric Press; 1990:91-115.

25.
Medical Research Council.
Clinical trial of the treatment of depressive illness: report to the Medical Research Council by its Clinical Psychiatry Committee.
BMJ.
1965;1:881-886.

26.
Sargant W, Slater E.
An Introduction to Physical Methods of Treatment in Psychiatry.
Baltimore, Md: Williams & Wilkins; 1964.

27.
Flint AJ, Rifat SL.
The effect of sequential antidepressant treatment on geriatric depression.
J Affect Disord.
1996;36:95-105.

28.
Danish University Antidepressant Group (DUAG).
Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study.
Psychopharmacology.
1986;90:131-138.

29.
Andersen IM, Tomenson BM.
The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants.
J Psychopharmacol.
1994;8:238-249.

30.
Roose SP, Glassman AH, Attia E, Woodring S.
Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia.
Am J Psychiatry.
1994;151:1735-1739.

31.
Reimherr F, Wood D, Byerley B, Brainard J, Grosser B.
Characteristics of responders to fluoxetine.
Psychopharmacol Bull.
1984;20:70-72.

32.
Tignol J, Stoker M, Dunbar G.
Paroxetine in the treatment of melancholia and severe depression.
Int Clin Psychopharmacol.
1992;7:91-94.

33.
Danish University Antidepressant Group (DUAG).
Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study.
J Affect Disord.
1990;18:289-299.

34.
Prudic J, Haskett RF, Mulsant B, et al.
Resistance to antidepressant medications and short-term clinical response to ECT.
Am J Psychiatry.
1996;153:985-992.

35.
de Montigny C, Cournoyer G, Morissette R, Langlois R, Caille G.
Lithium carbonate addition in tricylic antidepressant-resistant unipolar depression.
Arch Gen Psychiatry.
1983;40:1327-1334.

36.
Dinan TG, Barry S.
A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders.
Acta Psychiatr Scand.
1989;80:97-100.

37.
Bruijn JA, Moleman P, Mulder PG, van den Broek WW.
Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition.
J Clin Psychiatry.
1998;59:657-663.

38.
Heninger GR, Carney DS, Sternberg DE.
Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression.
Arch Gen Psychiatry.
1983;40:1335-1342.

39.
Joffe RT, Singer W, Levitt AJ, MacDonald C.
A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.
Arch Gen Psychiatry.
1993;50:387-393.

40.
Kantor D, McNevin S, Leichner P, Harper D, Krenn M.
The benefit of lithium carbonate adjunct in refractory depression: fact or fiction?
Can J Psychiatry.
1986;31:416-418.

41.
Thase ME, Kupfer DJ, Frank E, Jarrett DB.
Treatment of imipramine-resistant recurrent depression, II: an open clinical trial of lithium augmentation.
J Clin Psychiatry.
1989;50:413-417.

42.
Mulsant BH, Haskett RF, Prudic J, et al.
Low use of neuroleptic drugs in the treatment of psychotic major depression.
Am J Psychiatry.
1997;154:559-561.

43.
Endicott J, Spitzer RL.
A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia.
Arch Gen Psychiatry.
1978;35:837-844.

44.
Spitzer RL, Endicott J, Robins E.
Research diagnostic criteria: rationale and reliability.
Arch Gen Psychiatry.
1978;35:773-782.

45.
Hamilton M.
Development of a rating scale for primary depressive illness.
Br J Soc Psychol.
1967;6:278-296.

46.
Prien R, Kupfer D.
Continuation drug therapy for major depressive episodes: how long should it be maintained?
Am J Psychiatry.
1986;143:18-23.

47.
Prien RF, Koscis JH.
Long-term treatment of mood disorders.
In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven; 1995:1067-1080.

48.
d'Elia G.
Unilateral electroconvulsive therapy.
Acta Psychiatr Scand.
1970;215(suppl):1-98.

49.
Sackeim HA, Decina P, Prohovnik I, Malitz S.
Seizure threshold in electroconvulsive therapy: effects of sex, age, electrode placement, and number of treatments.
Arch Gen Psychiatry.
1987;44:355-360.

50.
Prudic J, Sackeim HA, Devanand DP.
Medication resistance and clinical response to electroconvulsive therapy.
Psychiatry Res.
1990;31:287-296.

51.
Fleiss JL.
The Design and Analysis of Clinical Experiments.
New York, NY: John Wiley & Sons; 1986.

52.
Cooper TB, Simpson GM.
Prediction of individual dosage of nortriptyline.
Am J Psychiatry.
1978;135:333-335.

53.
Cooper TB, Simpson GM.
The 24-hour lithium level as a prognosticator of dosage requirements: a 2-year follow-up study.
Am J Psychiatry.
1976;133:440-443.

54.
Cooper TB, Simpson GM.
Issues related to the prediction of optimum dosage.
In: Cooper TB, Gershon S, Kline NS, Schou M, eds. Lithium: Controversies and Unresolved Issues. Amsterdam, the Netherlands: Excerpta Medica; 1979:346-353.

55.
Miller MD, Paradis CF, Houck PR, et al.
Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale (CIRS).
Psychiatry Res.
1992;41:237-248.

56.
Guy W.
ECDEU Assessment Manual for Psychopharmacology.
Washington, DC: Superintendent of Documents, US Government Printing Office, US Dept of Health, Education, and Welfare; 1976. Publication 76-338.

57.
Kalbfleisch JD, Prentice RL.
Survival Models and Data Analysis.
New York, NY: John Wiley; 1980.

58.
Peto R, Peto J.
Asymptomatically efficient rank invariant procedure.
J R Stat Soc Ser A.
1972;135:185-207.

59.
McCall WV, Reboussin DM, Weiner RD, Sackeim HA.
Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects.
Arch Gen Psychiatry.
2000;57:438-444.

60.
Shapira B, Gorfine M, Lerer B.
A prospective study of lithium continuation therapy in depressed patients who have responded to electroconvulsive therapy.
Convuls Ther.
1995;11:80-85.

61.
Flint AJ, Rifat SL.
The effect of treatment on the two-year course of late-life depression.
Br J Psychiatry.
1997;170:268-272.

62.
Steering Committee of the American Psychiatric Association.
The Expert Consensus Guideline Series: treatment of bipolar disorder.
J Clin Psychiatry.
1996;57(suppl 12A):3-88.

63.
American Psychiatric Association.
Practice guideline for the treatment of patients with bipolar disorder.
Am J Psychiatry.
1994;151(12 suppl):1-36.

64.
Coppen A, Abou-Saleh MT, Milln P, et al.
Lithium continuation therapy following electroconvulsive therapy.
Br J Psychiatry.
1981;139:284-287.

65.
Abou-Saleh MT.
How long should drug therapy for depression be maintained?
Am J Psychiatry.
1987;144:1247-1248.

66.
Sargeant JK, Bruce ML, Florio LP, Weissman MM.
Factors associated with 1-year outcome of major depression in the community.
Arch Gen Psychiatry.
1990;47:519-526.

67.
Black DW, Goldstein RB, Nasrallah A, Winokur G.
The prediction of recovery using a multivariate model in 1471 depressed inpatients.
Eur Arch Psychiatry Clin Neurosci.
1991;241:41-45.

68.
Ernst C, Angst J.
The Zurich Study, XII: sex differences in depression: evidence from longitudinal epidemiological data.
Eur Arch Psychiatry Clin Neurosci.
1992;241:222-230.

69.
Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB.
Sex and depression in the National Comorbidity Survey, I: lifetime prevalence, chronicity and recurrence.
J Affect Disord.
1993;29:85-96.

70.
Simpson HB, Nee JC, Endicott J.
First-episode major depression: few sex differences in course.
Arch Gen Psychiatry.
1997;54:633-639.

71.
Zimmerman M, Coryell W, Pfohl B, Corenthal C, Stangl D.
ECT response in depressed patients with and without a DSM-III personality disorder.
Am J Psychiatry.
1986;143:1030-1032.

72.
Sareen J, Enns MW, Guertin JE.
The impact of clinically diagnosed personality disorders on acute and one-year outcomes of electroconvulsive therapy.
J ECT.
2000;16:43-51.

73.
Hyman SE, Nestler EJ.
Initiation and adaptation: a paradigm for understanding psychotropic drug action.
Am J Psychiatry.
1996;153:151-162.

74.
Suppes T, Baldessarini RJ, Faedda GL, Tohen M.
Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.
Arch Gen Psychiatry.
1991;48:1082-1088.

75.
Baldessarini RJ, Tondo L, Faedda GL, Suppes TR, Floris G, Rudas N.
Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders.
J Clin Psychiatry.
1996;57:441-448.

76.
Reynolds CF III, Frank E, Perel JM, et al.
High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression.
Am J Psychiatry.
1996;153:1418-1422.

next: Debate Rages Over Safety of ECT, or Shock Therapy, Used on Elderly
~ depression library articles
~ all articles on depression